Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PENTADECAPEPTIDE BPC-157, CIMETIDINE, RANITIDINE, BROMOCRIPTINE, AND ATROPINE EFFECT IN CYSTEAMINE LESIONS IN TOTALLY GASTRECTROMIZED RATS - A MODEL FOR CYTOPROTECTIVE STUDIES
Autore:
SIKIRIC P; MIKUS D; SEIWERTH S; GRABAREVIC Z; RUCMAN R; PETEK M; JAGIC V; TURKOVIC B; ROTKVIC I; MISE S; ZORICIC I; PERIC J; KONJEVODA P; PEROVIC D; JURINA L; HANZEVACKI M; SEPAROVIC J; GJURASIN M; JADRIJEVIC S; JELOVAC N; MIKLIC P; BULJAT G; MAROVIC A;
Indirizzi:
UNIV ZAGREB,FAC MED,DEPT PHARMACOL,SALATA 11,POB 916 ZAGREB 10000 CROATIA UNIV ZAGREB,MED & VET FAC,CTR DIGEST DIS ZAGREB 41000 CROATIA
Titolo Testata:
Digestive diseases and sciences
fascicolo: 5, volume: 42, anno: 1997,
pagine: 1029 - 1037
SICI:
0163-2116(1997)42:5<1029:PBCRBA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
INDUCED DUODENAL-ULCERS; DOPAMINE AGONISTS; RESTRAINT STRESS; H-2-RECEPTOR ANTAGONISTS; SOMATOSTATIN; ACID; ULCERATION; PEPTIDE; ORGANOPROTECTION; HISTAMINE;
Keywords:
PENTADECAPEPTIDE BPC 157; PEPTIDE BPC; TOTAL GASTRECTOMY; CYSTEAMINE; DUODENAL ULCERS; STANDARD ANTIULCER AGENTS; CYTOPROTECTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
62
Recensione:
Indirizzi per estratti:
Citazione:
P. Sikiric et al., "PENTADECAPEPTIDE BPC-157, CIMETIDINE, RANITIDINE, BROMOCRIPTINE, AND ATROPINE EFFECT IN CYSTEAMINE LESIONS IN TOTALLY GASTRECTROMIZED RATS - A MODEL FOR CYTOPROTECTIVE STUDIES", Digestive diseases and sciences, 42(5), 1997, pp. 1029-1037

Abstract

A superior effectiveness in various lesion assays was noted for the novel pentadecapeptide BPC 157, originated from human gastric juice protein (BPC) and claimed to be a cytoprotective agent. From this viewpoint, as a previously untreated experimental improvement to create an acid-free environmental for cytoprotection studies, total gastrectomy was done 24 hr before the ulcerogenic procedure. In the absence of stomach and gastric acid, the damaging effects of cysteamine (400 mg/kg subcutaneously, death 24 hr thereafter), to date thought to be an acid-related duodenal ulcerogen, and the BPC 157 cytoprotective effect (10 mug or 10 ng/kg intraperitoneally) were further challenged. BPC 157 wascompared with reference agents [cimetidine (50), ranitidine (10), omeprazole (10), bromocriptine (10) and atropine (10) (mg/kg intraperitoneally, 1 hr before cysteamine] known to be also cytoprotective. In naive rats, with intact stomach, all of them showed a strong beneficial effect. Interestingly, in gastrectomized animals, the application of BPC 157 or the reference agents before cysteamine significantly prevented the otherwise severe duodenal lesion development noted in the control gastrectomized cysteamine rats. In groups without cysteamine, no lesions were noted (laparotomy, gastrectomy only, 24 or 48 hr postsurgical period), nor was lesion potentiation seen in cysteamine-treated laparotomized animals. In summary, these findings-equal damaging effect ofcysteamine and equal protection of pentadecapeptide BPC 157 and reference agents in gastrectomized and rats with intact stomach-seem to be particularly relevant for a cytoprotective viewpoint. Without a stomach, the cysteamine damaging effect was convincingly defined as an essential gastric acid-independent injury (analogous to ethanol gastric lesions). Likewise, a high ''cytoprotective capacity,'' apparently acid independent, common for all tested agents (novel pentadecapeptide BPC 157, cimetidine, ranitidine, omeprazole and atropine) could be clearly stressed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/07/20 alle ore 04:59:04